INSULET CORPORATION

NASDAQ: PODD (Insulet Corporation)

Last update: 11 Dec, 2025, 1:28PM

294.53

-0.66 (-0.22%)

  • 1D -0.22%
  • 5D 11.18%
  • 1M 0.06%
  • 6M 6.21%
  • YTD 4.10%
  • 1Y 2.38%
  • 5Y 4.86%
Previous Close 295.19
Open 296.45
Volume 275,544
Avg. Volume (3M) 658,692
Market Cap 20,732,536,832
Price / Earnings (TTM) 86.12
Price / Earnings (Forward) 42.02
Price / Sales 7.40
Price / Book 13.04
52 Weeks Range
230.05 (-21%) — 354.88 (20%)
Earnings Date 6 Nov 2025
Profit Margin 18.29%
Operating Margin (TTM) 15.61%
Diluted EPS (TTM) 5.54
Quarterly Revenue Growth (YOY) 28.80%
Quarterly Earnings Growth (YOY) -31.30%
Total Debt/Equity (MRQ) 131.40%
Current Ratio (MRQ) 4.47
Operating Cash Flow (TTM) 406.50 M
Levered Free Cash Flow (TTM) 84.25 M
Return on Assets (TTM) 6.94%
Return on Equity (TTM) 37.92%

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Mixed
Medical Devices (Global) Mixed Mixed
Stock Insulet Corporation Bearish Bullish

AIStockmoo Score

0.0
Analyst Consensus 1.5
Insider Activity NA
Price Volatility 1.0
Technical Moving Averages 0.0
Technical Oscillators -2.5
Average 0.00

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
PODD 21 B - 86.12 13.04
DXCM 27 B - 38.83 10.13
SSII 1 B - - 20.66
IRTC 6 B - - 42.64
TMDX 5 B - 55.88 13.56
ESTA 2 B - - 122.85

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Sector Healthcare
Industry Medical Devices
Investment Style Mid Growth
% Held by Insiders 0.29%
% Held by Institutions 102.56%
52 Weeks Range
230.05 (-21%) — 354.88 (20%)
Price Target Range
274.00 (-6%) — 450.00 (52%)
High 450.00 (Canaccord Genuity, 52.79%) Buy
Median 380.00 (29.02%)
Low 274.00 (Barclays, -6.97%) Sell
Average 375.82 (27.60%)
Total 10 Buy, 1 Sell
Avg. Price @ Call 303.81
Firm Date Target Price Call Price @ Call
Stifel 04 Feb 2026 350.00 (18.83%) Buy 251.22
Barclays 12 Jan 2026 274.00 (-6.97%) Sell 278.55
07 Nov 2025 316.00 (7.29%) Hold 319.82
Bernstein 09 Jan 2026 380.00 (29.02%) Buy 289.04
Truist Securities 18 Dec 2025 390.00 (32.42%) Buy 292.88
21 Nov 2025 412.00 (39.89%) Buy 331.17
Canaccord Genuity 17 Dec 2025 450.00 (52.79%) Buy 289.57
24 Nov 2025 432.00 (46.68%) Buy 337.53
Evercore ISI Group 16 Dec 2025 370.00 (25.62%) Buy 288.73
BTIG 21 Nov 2025 380.00 (29.02%) Buy 331.17
13 Nov 2025 370.00 (25.62%) Buy 332.67
RBC Capital 21 Nov 2025 380.00 (29.02%) Buy 331.17
07 Nov 2025 370.00 (25.62%) Buy 319.82
UBS 19 Nov 2025 400.00 (35.81%) Buy 346.36
07 Nov 2025 355.00 (20.53%) Hold 319.82
Wells Fargo 07 Nov 2025 360.00 (22.23%) Buy 319.82
Jefferies 06 Nov 2025 400.00 (35.81%) Buy 323.40
Show more

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria